Conclusion
In conclusion, recognition and diagnosis of TA-TMA is challenging.
Clinical utility of complement blockage with eculizumab is limited in
terms of therapeutic efficacy, response monitoring and financial
implications. Further prospective research studies on alternative agents
are warranted to improve treatment and outcomes of TA-TMA.